Dynamics of T-cell responses following COVID-19 mRNA vaccination and breakthrough infection in older adults

3	
4	Sneha Datwani ¹ , Rebecca Kalikawe ¹ , Francis Mwimanzi ¹ , Sarah Speckmaier ² , Richard
5	Liang ² , Yurou Sang ¹ , Rachel Waterworth ¹ , Fatima Yaseen ³ , Hope R. Lapointe ² , Evan
6	Barad ^{1,2} , Mari L. DeMarco ^{4,5} , Daniel T. Holmes ^{4,5} , Janet Simons ^{4,5} , Julio S.G.
7	Montaner ^{3,6} , Marc G. Romney ^{4,5} , Zabrina L. Brumme ^{1,2*,#} , Mark A. Brockman ^{1,2,3,*,#}
8	
9	¹ Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
10	² British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
11	³ Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby,
12	Canada;
13	⁴ Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver,
14	Canada;
15	⁵ Department of Pathology and Laboratory Medicine, University of British Columbia,
16	Vancouver, Canada
17	⁶ Department of Medicine, University of British Columbia, Vancouver, Canada;
18	
19	*equal contributions
20	
21	#Corresponding authors: MAB, mark_brockman@sfu.ca; ZLB, zbrumme@sfu.ca
22	
23	Abstract: 248 words
24	Text: 3,093 words
25	Inserts: 5 (1 Table, 4 Figures)
26	Supplemental files: 8 (3 Supplemental Figures, 5 Supplemental Tables)
27	
28	
29	Footnotes
30	
31	Potential Conflicts of Interest: The authors have no conflicts of interest to declare.
32 22	Funding statement. This work was supported by the Dublic Health A genery of Canada
37	through a COVID 10 Immunology Task Force COVID 10 "Hot Spots" Award (2020
25	HO-000120 to MGR ZLB MAR) Additional funding was received from the Canadian
36	Institutes for Health Research (GA2-177713 and the Coronavirus Variants Rapid
37	Response Network (FRN-175622) to MAR) the Canada Foundation for Innovation
38	through Exceptional Opportunities Fund – COVID-19 awards (to MAB MLD ZLB)
39	FM was supported by a fellowship from the CIHR Canadian HIV Trials Network FY
40	and EB were supported by an SFU Undergraduate Research Award, MLD and ZLB hold
41	Scholar Awards from the Michael Smith Foundation for Health Research.
42	

43 ABSTRACT (248/250 words)

44	Introduction: While older adults generally mount weaker antibody responses to a
45	primary COVID-19 vaccine series, T-cell responses remain less well characterized in this
46	population. We compared SARS-CoV-2 spike-specific T-cell responses after two- and
47	three-dose COVID-19 mRNA vaccination and subsequent breakthrough infection in
48	older and younger adults.
49	
50	Methods: We quantified CD4+ and CD8+ T-cells reactive to overlapping peptides
51	spanning the ancestral SARS-CoV-2 spike protein in 40 older adults (median age 79) and
52	50 younger health care workers (median age 39), all COVID-19 naive, using an
53	activation induced marker assay. T-cell responses were further assessed in 24
54	participants, including 8 older adults, who subsequently experienced their first SARS-
55	CoV-2 breakthrough infection.
56	
57	
57	Results: A third COVID-19 mRNA vaccine dose significantly boosted spike-specific
58	Results: A third COVID-19 mRNA vaccine dose significantly boosted spike-specific CD4+ and CD8+ T-cell frequencies to above two-dose levels in older and younger adults.
58 59	Results: A third COVID-19 mRNA vaccine dose significantly boosted spike-specific CD4+ and CD8+ T-cell frequencies to above two-dose levels in older and younger adults. T-cell frequencies did not significantly differ between older and younger adults after
58 59 60	Results: A third COVID-19 mRNA vaccine dose significantly boosted spike-specific CD4+ and CD8+ T-cell frequencies to above two-dose levels in older and younger adults. T-cell frequencies did not significantly differ between older and younger adults after either dose. Multivariable analyses adjusting for sociodemographic, health and vaccine-
58 59 60 61	Results: A third COVID-19 mRNA vaccine dose significantly boosted spike-specific CD4+ and CD8+ T-cell frequencies to above two-dose levels in older and younger adults. T-cell frequencies did not significantly differ between older and younger adults after either dose. Multivariable analyses adjusting for sociodemographic, health and vaccine- related variables confirmed that older age was not associated with impaired cellular
57 58 59 60 61 62	Results: A third COVID-19 mRNA vaccine dose significantly boosted spike-specific CD4+ and CD8+ T-cell frequencies to above two-dose levels in older and younger adults. T-cell frequencies did not significantly differ between older and younger adults after either dose. Multivariable analyses adjusting for sociodemographic, health and vaccine- related variables confirmed that older age was not associated with impaired cellular responses. Instead, the strongest predictors of CD4+ and CD8+ T-cell frequencies post-
 57 58 59 60 61 62 63 	Results: A third COVID-19 mRNA vaccine dose significantly boosted spike-specific CD4+ and CD8+ T-cell frequencies to above two-dose levels in older and younger adults. T-cell frequencies did not significantly differ between older and younger adults after either dose. Multivariable analyses adjusting for sociodemographic, health and vaccine- related variables confirmed that older age was not associated with impaired cellular responses. Instead, the strongest predictors of CD4+ and CD8+ T-cell frequencies post- third-dose were their corresponding post-second-dose frequencies. Breakthrough
 57 58 59 60 61 62 63 64 	Results: A third COVID-19 mRNA vaccine dose significantly boosted spike-specific CD4+ and CD8+ T-cell frequencies to above two-dose levels in older and younger adults. T-cell frequencies did not significantly differ between older and younger adults after either dose. Multivariable analyses adjusting for sociodemographic, health and vaccine- related variables confirmed that older age was not associated with impaired cellular responses. Instead, the strongest predictors of CD4+ and CD8+ T-cell frequencies post- third-dose were their corresponding post-second-dose frequencies. Breakthrough infection significantly increased both CD4+ and CD8+ T cell frequencies, to comparable

- 66 HLA-A*02:03 and higher post-vaccination CD8+ T-cell frequencies, which may be
- 67 attributable to numerous strong-binding HLA-A*02:03-specific CD8+ T-cell epitopes in
- 68 spike.
- 69
- 70 Conclusion: Older adults mount robust T-cell responses to two- and three-dose COVID-
- 71 19 mRNA vaccination, which are further boosted following breakthrough infection.

72 INTRODUCTION

73	In many jurisdictions, older adults were prioritized to receive COVID-19 vaccines
74	and boosters due to their increased risk of severe outcomes following SARS-CoV-2
75	infection ¹⁻³ . While vaccination has been highly effective at preventing severe disease in
76	this group ⁴ , vaccine responses in older adults can nevertheless be blunted by age-related
77	immune impairments, or elevated frequencies of chronic health conditions that can
78	dampen adaptive immune responses ⁵⁻⁹ . Indeed, after COVID-19 vaccines were rolled out
79	globally, observational studies revealed that older adults generally mounted weaker
80	binding and neutralizing antibody to the primary vaccine series ¹⁰⁻¹⁵ , leading to
81	widespread recommendations that this group receive third vaccine doses and regular
82	booster vaccinations ^{16,17} . Comparably fewer studies however have investigated cellular
83	immune responses to COVID-19 vaccination – namely, CD4+ helper T cells that play a
84	central role in the generation of antigen-specific B cells and antibody responses, and
85	CD8+ cytotoxic T cells that recognize and eliminate virus-infected cells ¹⁸ $-$ in older
86	compared to younger adults. While mRNA vaccines can induce strong T cell
87	responses ^{19,20} , evidence suggests that the frequency of spike-specific CD4+ T cells
88	following COVID-19 vaccination may be lower in older adults ^{11,13,21} . An improved
89	understanding of age-associated differences in T cell responses to COVID-19 mRNA
90	vaccines will help to inform future efforts to enhance protective immunity in older adults.
91	Here, we investigated the dynamics of spike-specific CD4+ and CD8+ T cell responses
92	elicited after two and three doses of COVID-19 mRNA vaccine in a cohort of 40 older
93	adults and 50 younger healthcare workers who remained naive to SARS-CoV-2 during
94	this time. We additionally investigated spike-specific CD4+ and CD8+ T cell responses

95	in a subset of 24 individuals, including 8 older adults, who subsequently experienced
96	their first SARS-CoV-2 breakthrough infection between one and six months after
97	receiving three vaccine doses. Finally, we explored associations between HLA class I
98	allele carriage and the magnitude of spike-specific CD8+ T cell frequencies after two and
99	three COVID-19 mRNA vaccine doses.
100	
101	METHODS
102	Participants. Our cohort, based in British Columbia (BC) Canada, has been described
103	previously ²² . Here, we studied a randomly selected subset of 50 healthcare workers
104	(HCW) and 40 older adults (OA, age >65 years) who remained COVID-19 naive until at
105	least one month after their third COVID-19 mRNA vaccine dose (Table 1).
106	
107	Ethics approval. Written informed consent was obtained from all participants or their
108	authorized decision makers. This study was approved by the University of British
109	Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards.
110	
111	Antibody assays. We had previously quantified IgG-binding antibodies in serum against
112	the ancestral SARS-CoV-2 spike receptor binding domain (RBD) using the V-plex
113	SARS-CoV-2 (IgG) ELISA kit (Panel 22; Meso Scale Diagnostics) ^{14,15,22} . Serum was
114	diluted 1:10000 and reported in World Health Organization (WHO) International
115	Standard Binding Antibody Units (BAU)/mL using the manufacturer-supplied
116	conversions. SARS-CoV-2 infections were detected by the development of serum
117	antibodies against Nucleocapsid (N) using the Elecsys Anti-SARS-CoV-2 assay (Roche

118 Diagnostics), combined with diagnostic (PCR- and/or rapid-antigen-test-based)

- 119 information where available.
- 120

121	<i>T-cell assays.</i> Cryopreserved peripheral blood mononuclear cells (PBMCs) were thawed
122	and diluted in TexMACS media (Miltenyi Biotec, Cat#130-097-196). PBMCs were
123	stimulated at 1 x 10^6 cells per well for 24 hours with peptide pools spanning the SARS-
124	CoV-2 ancestral spike protein (15-mers, overlapping by 11 amino acids) (Miltenyi
125	Biotec, Cat#130-127-953) in duplicate in a 96-well U-bottom plate. PBMC were
126	incubated with DMSO only (no peptide) as a negative control and 2 μ g/ml Cytostim
127	reagent (Miltenyi Biotec, Cat#130-092-172) as a positive control. Following stimulation,
128	cells were labeled with CD8-APC/Cyanine7 (Biolegend, Cat#301016), CD4-FITC
129	(Biolegend, Cat#300538), CD137-APC (Biolegend, Cat#309810), CD69-PE (BD,
130	Cat#555531), OX40-PE-Cy7 (Biolegend, Cat#350012), CD3-PerCP/Cyanine5.5
131	(Biolegend, Cat#317336) CD14-V500 (BD, Cat#561391), CD19-V500 (BD,
132	Cat#561121) and 7-AAD Viability Staining Solution (Biolegend, Cat#420404). Data
133	were acquired on a Beckman Coulter Cytoflex flow cytometer, with a minimum of
134	10,000 CD3+ T cells assayed per participant. After identifying CD3+CD4+ and
135	CD3+CD8+ T cell subsets, the percentage of stimulated cells was determined based on
136	upregulation of activation markers, using CD137 and OX40 for CD4+ T cells and CD137
137	and CD69 for CD8+ T cells (see gating strategy in Figure S1). Data were analyzed in
138	FlowJo version 10.8.1.
139	

140	HLA class I genotyping. Genomic DNA was isolated from 50 µl whole blood using the
141	NucliSENS EasyMag system (BioMerieux). HLA class I genotyping was performed by
142	locus-specific Polymerase Chain Reaction (PCR) amplification of the region spanning
143	exons 2 and 3 of the HLA-A, B and -C loci, as reported previously ²³ . Amplicons were bi-
144	directionally sequenced on an ABI 3730xl automated Sanger DNA sequencer using
145	BigDye (v3.1) chemistry (Applied Biosystems). Chromatograms were analyzed using the
146	semiautomatic base-calling software RECall ²⁴ , with the resulting bulk sequences
147	interpreted to subtype-level resolution using in-house software.
148	
149	<i>Epitope prediction</i> . Peptides derived from ancestral spike protein (GenBank:
150	NC_045512.2) that are likely to bind to HLA-A*02:01 and/or A*02:03 were predicted
151	using NetMHCpan-4.1 (https://services.healthtech.dtu.dk/services/NetMHCpan-4.1; ²⁵).
152	Potential 8-, 9-, and 10- amino acid epitopes were determined for both alleles using
153	default thresholds for strong binders (% Rank <0.5) and weak binders (% Rank 0.5-2).
154	
155	Statistical analyses. Continuous variables were compared using the Mann-Whitney U-
156	test (for unpaired data) or Wilcoxon test (for paired measures). Relationships between
157	continuous variables were assessed using Spearman's correlation. Zero-inflated beta
158	regressions were used to investigate the relationship between age and vaccine-induced T-
159	cell responses using a confounder model that adjusted for variables that could influence
160	these responses, or that differed in prevalence between groups. These regressions model
161	the response variable as a beta-distributed random variable whose mean is given by a
162	linear combination of the predictor variables (after a logit transformation). Beta

163	distributions are bounded below and above by 0 and 100%, making this a standard choice
164	of regression for frequency data. A beta distribution however does not admit values of 0
165	or 100. As our data included some non-responders (<i>i.e.</i> 0 values) we used a zero-inflated
166	beta distribution, which allows for zeros in the data. For analyses performed after two-
167	dose vaccination, included variables were: age (per year), sex at birth (female as
168	reference), ethnicity (non-white as reference), number of chronic conditions (per
169	additional), mRNA-1273-containing initial vaccine regimen (dual BNT162b2 vaccination
170	as reference) and the interval between first and second doses (per day). Analyses
171	performed after three-dose vaccination also included the third COVID-19 mRNA dose
172	brand (BNT162b2 as reference), the interval between second and third doses (per day),
173	and the % spike-specific T-cells after two doses (per percent increase). All tests were
174	two-tailed, with p<0.05 considered statistically significant. For the analyses of the
175	relationships between HLA class I allele carriage, multiple comparisons were addressed
176	using a q-value (false discovery rate) approach ²⁶ , with associations p<0.05 and q<0.2
177	considered statistically significant. Analyses were conducted using Prism v9.2.0
178	(GraphPad) and in R.

179

180 **RESULTS**

181 *Participant characteristics*

182 Characteristics of the 40 older adults (OA) and 50 younger health care workers 183 (HCW), all of whom remained COVID-19 naive until at least one month after their third 184 vaccine dose, are shown in **Table 1**. OA and HCW were a median of 79 and 39 years old, 185 respectively (overall range 24-93 years old), and predominantly female. OA were

186	predominantly of white ethnicity (73%, compared to 46% of HCW) and had more
187	chronic health conditions (median of 1, interquartile range [IQR] 0-2 in OA versus 0
188	[IQR 0-1] in HCW). Most participants (80% of OA and 96% of HCW) initially received
189	two doses of BNT162b2; the remainder received two doses of mRNA-1273 or a
190	heterologous mRNA vaccine regimen. Second doses were administered a median of ~ 3
191	months after the first. Third vaccine doses were predominantly mRNA-1273 (62% of OA
192	and 50% of HCW), which were administered in an age-dependent manner per local
193	guidelines: OA were eligible for 100 mcg whereas HCW were eligible for 50 mcg (all
194	BNT162b2 doses were 30 mcg). Third doses were administered a median of 6 months
195	after the second. A total of 20% of OA and 32% of HCW experienced their first SARS-
196	CoV-2 infection between one and six months post-third dose, where these were likely
197	Omicron BA.1 or BA.2 infections based on local molecular epidemiology trends ²⁷ . The
198	post-infection follow-up visit occurred 53 (IQR 40-119) days later for OA and 63 (IQR
199	31-104) days later for HCW.
200	
201	CD4+ and CD8+ T-cell responses following two and three COVID-19 vaccine doses
202	Prior to vaccination, the percentage of spike-specific CD4+ and CD8+ T cells,
203	measured in a subset of 10 OA and 10 HCW, was negligible (Figures 1A, 1B).
204	Following two vaccine doses, the percentage of spike-specific CD4+ T cells increased
205	significantly from pre-vaccine levels (paired measures p=0.002 for both OA and HCW),
206	reaching a median 0.25% (IQR 0.14-0.57%) in OA and a median 0.42% (IQR 0.14-

- 207 0.66%) in HCW, a difference that was not statistically significant between groups
- 208 (p=0.28; Figure 1A). A third vaccine dose further boosted the percentage of spike-

209	specific CD4+ T-cells (paired measures p<0.0001 for both OA and HCW), reaching a
210	median 0.62% (IQR 0.27-0.91) in OA compared to a median 0.77% (IQR 0.45-1.08) in
211	HCW, a difference that was not statistically significant between groups (p=0.07) (Figure
212	1A).
213	CD8+ T cell responses also increased significantly from pre-vaccine levels
214	following two vaccine doses (paired measures p=0.002 in both groups), reaching a
215	median 0.24% (IQR 0.13-0.45%) in OA and a median 0.33% (IQR 0.16-0.63%) in HCW,
216	a difference that was not statistically significant between groups (p=0.11; Figure 1B). A
217	third vaccine dose further boosted the percentage of spike-specific CD8+ T-cells (paired
218	measures p<0.0001 for both groups) to a median 0.62% (IQR 0.34-1.08%) in OA and a
219	median 0.78% (IQR 0.42-1.18%) in HCW, a difference that was not statistically
220	significant between groups (p=0.39; Figure 1B).
221	We observed no correlation between age and the percentage of spike-specific
222	CD4+ or CD8+ T-cells after either the second or third vaccine dose, when age was
223	assessed as a continuous variable (Spearman's ρ ranged from = -0.14 to -0.03; all p>0.20;
224	not shown). Moreover, we confirmed that age remained not significantly associated with
225	vaccine-induced T-cell responses after adjusting for relevant sociodemographic, health
226	and vaccine-related variables (Tables S1 and S2). Rather, the strongest predictor of the
227	% of spike-specific CD4+ and CD8+ T-cells following three vaccine doses was the
228	corresponding % of spike-specific T-cells following two doses (Table S2). For example,
229	the zero-inflated beta regression estimates for the impact of each 1% increment in post-
230	second dose T-cell frequencies on post-third dose frequencies was 0.69 for CD4+ T-cells
231	$(p=2\times10^{-16})$ and 0.77 for CD8+ T-cells $(p=1\times10^{-13})$ (Table S2). To interpret these

232	estimates, which do not translate the effects of the predictors linearly to the predicted
233	mean: if the value of the linear predictor was x for a given set of values of the predictors,
234	and the % of spike-specific CD4+ T-cells after two vaccine doses was increased by 1%,
235	the resulting value of the linear predictor would now be $x + 0.69$, which translates to a
236	non-linear increase in the regressed mean from $100 * logit(x)$ to $100 * logit(x + 0.69)$,
237	where the factor of 100 converts the proportions to percentages. Enhanced CD4+ T-cell
238	frequencies after three vaccine doses were also associated with male sex, having received
239	mRNA-1273 as a third vaccine dose, and – somewhat surprisingly – a higher number of
240	health conditions, though these correlates were all far weaker than the post-second-dose
241	T cell responses (estimates 0.13-0.23; p=0.03 to 0.006; Table S2). We hypothesize that
242	association between more health conditions and better responses is because individuals
243	with such conditions benefited particularly from a third dose, after adjusting for post-
244	second-dose responses. White ethnicity was also weakly associated with lower CD4+ T-
245	cell frequencies after two vaccine doses (estimate -0.38; p=0.03; Table S1).
246	

247 Correlations between vaccine-induced humoral and T-cell responses

The percentage of spike-specific CD4+ and CD8+ T cells correlated strongly with one another after the second vaccine dose (Spearman's ρ =0.60; p<0.0001) as well as after the third dose (Spearman's ρ =0.59; p<0.0001; **Figure 2A**). No correlation however was observed between the magnitude of the COVID-19 vaccine antibody response, in terms of serum anti-spike Receptor Binding Domain (RBD) IgG concentrations after either the second or third vaccine dose, and the percentage of spike-specific CD4+ T-cells at those

times (Spearman's $\rho = -0.09$, p=0.41 for post-second dose; $\rho = -0.11$, p=0.32 for post-

third dose; **Figure 2B**).

256

257 Correlations between HLA class I genotypes and CD8+ T-cell responses

258 Participants expressed a total of 29 different HLA-A, 42 HLA-B and 23 HLA-C 259 alleles, defined at the subtype level (Figure S2). Exploratory analyses that included all 260 HLA alleles observed in a minimum of 5 participants revealed that, following three 261 vaccine doses, expression of HLA-A*02:03 was associated with higher spike-specific 262 CD8+ T cell response frequencies after correcting for multiple comparisons (p=0.01; 263 q=0.08), while expression of B*39:01, B*44:03, or C*07:01 was associated with lower 264 spike-specific CD8+ T cell response frequencies (all p < 0.03, q < 0.13) (Table S3). After 265 correcting for multiple comparisons, we did not identify any HLA class I alleles that were 266 significantly associated with spike-specific CD8+ T cell response frequencies after two 267 vaccine doses, but the top allele after two vaccine doses was also A*02:03 (p=0.02; 268 q=0.34; not shown). 269 To further explore the interaction with A*02:03, we used NetMHCpan-4.1²⁵ to 270 identify all 8-, 9-, and 10-amino acid spike epitopes that are predicted to bind to this 271 allele or to the common and closely related A*02:01 allele, which showed no beneficial 272 impact on CD8+ T cell responses after three vaccine doses (p=0.46, q=0.56; Table S3). 273 In total, 29 strong binders (% Rank < 0.5) and 56 weak binders (% Rank 0.5-2) were 274 observed for A*02:03, compared to 20 strong binders and 58 weak binders for A*02:01

275 (Table S4). A cumulative view of strong binders, plotted by % Rank, is shown in Figure

3A. An analysis of 30 shared epitopes that displayed strong binding affinity for either

277	allele further revealed that these epitopes were frequently predicted to bind more strongly
278	to A*02:03 than A*02:01 (Wilcoxon matched pairs test, p=0.009) (Figure 3B and Table
279	S5). Notably, seven weak-binding A*02:01 epitopes (all with % Ranks of \sim 1 to 2) were
280	predicted to bind A*02:03 strongly, while only one moderate-binding A*02:03 epitope
281	(GLTVLPPLL, % Rank 0.69) was predicted to bind strongly to A*02:01 (% Rank 0.26)
282	(Figure 3B). These results suggest that higher spike peptide affinity for A*02:03
283	contributes to enhanced CD8+ T cell responses following vaccination.
284	
285	Breakthrough infection boosts CD4+ and CD8+ T-cell responses
286	Post-vaccination breakthrough SARS-CoV-2 infection, which was observed in 8
287	(20%) OA and 16 (32%) HCW, further boosted the percentage of both spike-specific
288	CD4+ and CD8+ T-cells (p≤0.008 for all paired longitudinal comparisons; Figures 4A,
289	4B). The median percentage of spike-specific CD4+ T-cells increased to 0.73% (IQR
290	0.58-1.10) in OA and 0.86% (IQR 0.51-1.18) in HCW (between-group comparison
291	p=0.78; Figure 4A) while the median percentage of spike-specific CD8+ T-cells
292	increased to 0.98% (IQR 0.81-1.77) in OA and 1.13% (IQR 0.71-1.87) in HCW
293	(between-group comparison p=0.66; Figure 4B). A full longitudinal representation of
294	CD4+ and CD8+ T cell responses induced by vaccination and breakthrough infection, in
295	all studied participants, is shown in Figure S3.
296	
297	DISCUSSION
298	We observed that the frequencies of SARS-CoV-2 spike-specific CD4+ and CD8+ T
299	cells were not significantly different between older and younger adults after two doses of

300 COVID-19 mRNA vaccine, and that these responses were enhanced similarly by a third 301 vaccine dose regardless of age. Furthermore, both older and younger adults mounted 302 robust T cell responses following a post-vaccine breakthrough infection. These results are 303 consistent with a recent report showing that spike-specific T cell responses measured 304 using an AIM assay were equivalent in older and younger adults after two doses of 305 mRNA vaccine²¹, though another study reported impaired T cell effector function, 306 including lower cytokine production, in older adults following two vaccine doses¹³. Prior 307 studies have also found weaker T cell responses in older adults after only one vaccine 308 dose^{11,21,28}, but we did not examine this time point here. We also observed no association 309 between CD4+ T cell responses and RBD-specific IgG antibodies after either two or 310 three vaccine doses, suggesting that sufficient T cell help was provided to stimulate 311 spike-specific B cell responses despite a wide range of antigen-specific CD4+ T cell 312 frequencies. While our results do not completely rule out the possibility of age-related 313 dysfunction in vaccine-induced T cells among older adults, our data suggest that the 314 impact of any age-associated T cell impairment is likely to be modest after the second 315 and third vaccine dose. 316

Our data also indicate that HLA class I alleles modulate the frequency of spikespecific CD8+ T cell responses following vaccination. Notably, participants expressing HLA-A*02:03 exhibited higher CD8+ T cell responses, while individuals expressing B*39:01, B*44:03, or C*07:01 exhibited lower responses (though these associations only reached statistical significance after three vaccine doses). Bioinformatics analyses predicted a higher number of spike peptides that bound with high affinity to HLA-A*02:03 compared to the closely related A*02:01 allele (which was not associated with a

323	better vaccine response), suggesting that A*02:03 may elicit immunodominant responses
324	to a broader array of vaccine-derived antigens. Several studies have reported associations
325	between HLA genotype and COVID-19 severity or predicted COVID-19 vaccine
326	immunogenicity ²⁹⁻³³ , which may underpin ethnicity-related differences in T cell
327	responses that have been observed in some contexts ^{34,35} . Indeed, A*02:03 occurs most
328	frequently in individuals of South and East Asian ancestry, and therefore may contribute
329	to enhanced T cell responses to COVID-19 vaccines in this population ³⁵ . Additional
330	studies are needed to examine these HLA associations in greater detail.
331	This study has some limitations. While the AIM assay provides a very sensitive
332	method to quantify spike-specific CD4+ and CD8+ T cells, we did not analyze T cell
333	functions such as cytokine production or proliferation that could reveal differences in the
334	effector activity of vaccine- or infection-induced responses. Since T cell responses were
335	measured using peptide pools, we cannot comment on the relative dominance of
336	individual spike epitopes (or host HLAs), nor potential changes in the distribution of
337	these responses over time. Furthermore, we examined T cell responses using only
338	peptides spanning the ancestral spike protein, which match the vaccine antigen but may
339	not fully account for responses elicited against SARS-CoV-2 variants following
340	breakthrough infection. Finally, we did not assess T cell responses after the first dose of
341	COVID-19 mRNA vaccine, when age-related differences in immune cell frequency or
342	function may be more apparent.
343	In summary, our study provides evidence that repeated exposure to SARS-CoV-2
344	spike antigen, either via vaccination or infection, induces steadily higher T cell
345	frequencies in adults of all ages, at least up to 4 exposures. Importantly, our results also

346	indicate that COVID-19-naive older adults mount robust cellular immune responses after
347	two and three doses of COVID-19 mRNA vaccine, as well as after subsequent
348	breakthrough infection, that are comparable in magnitude to those of younger adults.
349	These results further underscore the benefits of COVID-19 vaccination in this population.
350	
351	
352	AUTHOR CONTRIBUTIONS
353	ZLB and MAB led the study. HRL and YS coordinated the study. SD, RK, FM,
354	SS, YS, RW, FY and EB processed specimens and collected data under the supervision
355	of ZLB and MAB. SD, RL, MAB and ZLB analyzed data. MLD, DTH, JS, JSGM and
356	MGR contributed to cohort establishment and/or SARS-CoV-2 serum antibody
357	quantification. SD, ZLB and MAB wrote the manuscript. All authors contributed to
358	manuscript review and editing.
359	
360	ACKNOWLEDGEMENTS
361	We thank the leadership and staff of Providence Health Care, St. Paul's Hospital,
362	the BC Centre for Excellence in HIV/AIDS, the Hope to Health Research and Innovation
363	Centre, and Simon Fraser University for supporting this project. We also thank the
364	participants, without whom this study would not have been possible.
365	
366	FUNDING STATEMENT
367	This work was supported by the Public Health Agency of Canada through a
368	COVID-19 Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120

- to MGR, ZLB, MAB). Additional funding was received from the Canadian Institutes for
- 370 Health Research (GA2-177713 and the Coronavirus Variants Rapid Response Network
- 371 (FRN-175622) to MAB), the Canada Foundation for Innovation through Exceptional
- 372 Opportunities Fund COVID-19 awards (to MAB, MLD, ZLB). FM holds a fellowship
- 373 from the CIHR Canadian HIV Trials Network. FY and EB were supported by an SFU
- 374 Undergraduate Research Award. MLD and ZLB hold Scholar Awards from the Michael
- 375 Smith Foundation for Health Research.

Table 1: Participant characteristics

Characteristic	OA (n=40)	HCW (n=50)
Sociodemographic and health variables ^a	(11 40)	(1 30)
Age in years, median [IOR]	79 [73-83]	39 [32-50]
Female sex at birth. n (%)	27 (68%)	37 (74%)
Ethnicity, n (%)		()
White	29 (73%)	23 (46%)
Asian	10 (25%)	22 (44%)
Other	1 (2%)	5 (10%)
Number of chronic health conditions, median [IQR] ^a	1 [0-2]	0 [0-1]
Vaccine details		
Initial regimen		
BNT162b2 - BNT162b2	32 (80%)	48 (96%)
mRNA-1273 - mRNA-1273	7 (18%)	1 (2%)
heterologous mRNA	1 (2%)	1 (2%)
Third dose		
BNT162b2	15 (38%)	25 (50%)
mRNA-1273	25 (62%)	25 (50%)
Days between first and second doses, median [IQR]	78 [45-86]	97 [91-101]
Days between second and third doses, median [IQR]	169 [160-231]	210 [199-231]
Post-3rd vaccine dose SARS-CoV-2 infections, n (%) ^c 8 (20%) 16 (32%)		
Days between breakthrough infection and subsequent sampling	53 [40-119]	63 [31-104]
76 ^a Sociodemographic health and vaccine data were collected	by self-report and	1 confirmed

376 ^aSociodemographic, health, and vaccine data were collected by self-report and confirmed

377 through medical records where available.

^bChronic conditions were defined as hypertension, diabetes, asthma, obesity, chronic diseases 378

of lung, liver, kidney, heart or blood, cancer, and immunosuppression due to chronic 379 380 conditions or medication.

^cAll SARS-CoV-2 infections occurred between one and six months after the third vaccine 381 dose.

382

384 FIGURE LEGENDS

385 Figure 1. SARS-CoV-2 spike-specific T-cell frequencies before and after COVID-19

- 386 **mRNA vaccination.** *Panel A:* Spike-specific CD4+ T-cell frequencies before and after
- 387 two and three-dose COVID-19 vaccination. Older Adults (OA) are in orange; younger
- 388 Health Care Workers (HCW) are in blue. All participants are COVID-19 naive. Red bars
- 389 indicate median and IQR. The Mann-Whitney U-test was used for between-group
- 390 comparisons and the Wilcoxon matched pairs test was used for longitudinal paired
- 391 comparisons. P-values are not corrected for multiple comparisons. Panel B: Same as
- 392 panel A, but for spike-specific CD8+ T-cell frequencies.
- 393

394 Figure 2. Correlations between cellular and humoral immune measures after two

395 and three-dose COVID-19 mRNA vaccination. Panel A: Correlation between spike-

396 specific CD4+ and CD8+ T-cell frequencies one month after the second dose (open

397 circles) and one month after the third dose (closed circles) in the combined cohort. *Panel*

398 B: Correlation between spike-specific CD4+ T-cell frequencies and spike-specific IgG

399 binding antibodies, measured in one month after the second dose (open circles) and one

400 month after the third dose (closed circles) in the combined cohort. All participants are

401 COVID-19 naive.

402

403 Figure 3. Comparison of HLA-A*02:01 and A*02:03 predicted strong-binding

- 404 epitopes in SARS-CoV-2 spike. Panel A: Cumulative frequencies of predicted strong-
- 405 binding epitopes in SARS-CoV-2 spike restricted by HLA-A*02:01 (blue line) and
- 406 A*02:03. Epitope predictions were performed using NetMHCpan4.1²⁵, which defines

407	strong binders as those with % Ranks of 0.5 or lower. The lower the % Rank, the stronger
408	the predicted binding. Panel B: Epitope binding ranks for 30 spike epitopes that were
409	predicted to bind strongly to either A*02:01 or A*02:03. Epitopes that are predicted to
410	bind more strongly to A*02:03 are linked by green lines, with seven epitopes that were
411	predicted to have the most substantially enhanced A*02:03 binding listed in green next to
412	their corresponding points. Epitopes that are predicted to bind more strongly to A*02:01
413	are linked by red dotted lines, with one epitope predicted to have the most substantially
414	enhanced A*02:01 binding listed in red next to its corresponding point. The shaded area
415	denotes the threshold for strong binders. P-value computed using the Wilcoxon matched
416	pairs test.
417	
418	Figure 4. SARS-CoV-2 spike-specific T-cell frequencies in a subset of participants
419	who experienced their first SARS-CoV-2 infection after receiving three vaccine
420	doses. Panel A: Spike-specific CD4+ T-cell frequencies in a subset of 8 OA (orange) and
421	16 HCW (blue) after three-dose COVID-19 vaccination while participants were still
422	COVID-19-naive, and after a subsequent breakthrough SARS-CoV-2 infection. The
423	Mann-Whitney U-test was used for between-group comparisons and the Wilcoxon
424	matched pairs test was used for longitudinal paired comparisons. P-values are not
425	corrected for multiple comparisons. Panel B: Same as panel A, but for spike-specific

426 CD8+ T-cell responses.

427

428

430 **REFERENCES**

431 432	1.	Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. <i>JAMA</i> 2020; 323 (18): 1775-6.
433 434 435	2.	Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. <i>JAMA</i> 2020; 323 (20): 2052-9.
436 437	3.	Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19- related death using OpenSAFELY. <i>Nature</i> 2020; 584 (7821): 430-6.
438 439	4.	Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>N Engl J Med</i> 2020; 383 (27): 2603-15.
440 441	5.	Goronzy JJ, Li G, Yang Z, Weyand CM. The janus head of T cell aging - autoimmunity and immunodeficiency. <i>Front Immunol</i> 2013; 4 : 131.
442 443 444	6.	Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. <i>Lancet</i> 2005; 366 (9492): 1165-74.
445 446	7.	Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. <i>N Engl J Med</i> 2007; 357 (14): 1373-81.
447 448	8.	Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. <i>Nat Immunol</i> 2013; 14 (5): 428-36.
449 450	9.	Goronzy JJ, Weyand CM. Mechanisms underlying T cell ageing. <i>Nat Rev Immunol</i> 2019; 19 (9): 573-83.
451 452	10.	Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. <i>N Engl J Med</i> 2022; 386 (4): 340-50.
453 454	11.	Collier DA, Ferreira I, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. <i>Nature</i> 2021; 596 (7872): 417-22.
455 456	12.	Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. <i>N Engl J Med</i> 2021; 385 (24): e84.
457 458 459	13.	Palacios-Pedrero MA, Jansen JM, Blume C, et al. Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults. <i>Nat Aging</i> 2022; 2 (10): 896-905.
460 461 462	14.	Mwimanzi F, Lapointe HR, Cheung PK, et al. Impact of age and SARS-CoV-2 breakthrough infection on humoral immune responses after three doses of COVID-19 mRNA vaccine. <i>Open Forum Infectious Diseases</i> 2023; Accepted, In Press.

463 464 465	15.	Mwimanzi F, Lapointe HR, Cheung PK, et al. Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. <i>J Infect Dis</i> 2022; 226 (6): 983-94.
466 467	16.	US Food and Drug Administration. FDA Authorizes Booster Dose of Pfizer- BioNTech COVID-19 Vaccine for Certain Populations. fda.gov; 2021.
468 469	17.	Bowman E. A CDC Panel Backs Booster Shots For Older Adults, A Step Toward Making Them Available. 'National Public Radio, USA. 2021 23 Sept 2021.
470 471	18.	Moss P. The T cell immune response against SARS-CoV-2. <i>Nat Immunol</i> 2022; 23 (2): 186-93.
472 473 474	19.	Painter MM, Mathew D, Goel RR, et al. Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. <i>Immunity</i> 2021; 54 (9): 2133-42 e3.
475 476	20.	Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. <i>Nature</i> 2020; 586 (7830): 594-9.
477 478 479	21.	Jo N, Hidaka Y, Kikuchi O, et al. Impaired CD4(+) T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination. <i>Nat Aging</i> 2023; 3 (1): 82-92.
480 481 482	22.	Brockman MA, Mwimanzi F, Lapointe HR, et al. Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. <i>J Infect Dis</i> 2022; 225 (7): 1129-40.
483 484 485	23.	Brumme ZL, Brumme CJ, Chui C, et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. <i>J Infect Dis</i> 2007; 195 (11): 1694-704.
486 487 488	24.	Woods CK, Brumme CJ, Liu TF, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. <i>J Clin Microbiol</i> 2012; 50 (6): 1936-42.
489 490 491 492	25.	Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. <i>Nucleic Acids Res</i> 2020; 48 (W1): W449-W54.
493 494	26.	Storey JD, Tibshirani R. Statistical significance for genomewide studies. <i>Proc Natl Acad Sci U S A</i> 2003; 100 (16): 9440-5.
495 496	27.	BC Centre for Disease Control. Weekly update on Variants of Concern. 2022. http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data.

497 498 499	28.	Muller L, Andree M, Moskorz W, et al. Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. <i>Clin Infect Dis</i> 2021; 73 (11): 2065-72.
500 501 502	29.	Bose T, Pant N, Pinna NK, Bhar S, Dutta A, Mande SS. Does immune recognition of SARS-CoV2 epitopes vary between different ethnic groups? <i>Virus Res</i> 2021; 305 : 198579.
503 504	30.	Rao V, Chandra N. In-silico study of influence of HLA heterogeneity on CTL responses across ethnicities to SARS-CoV-2. <i>Hum Immunol</i> 2022; 83 (12): 797-802.
505 506	31.	Bertinetto FE, Magistroni P, Mazzola GA, et al. The humoral and cellular response to mRNA SARS-CoV-2 vaccine is influenced by HLA polymorphisms. <i>HLA</i> 2023.
507 508	32.	Srivastava A, Hollenbach JA. The immunogenetics of COVID-19. <i>Immunogenetics</i> 2023; 75 (3): 309-20.
509 510 511	33.	Sacco K, Castagnoli R, Vakkilainen S, et al. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. <i>Nat Med</i> 2022; 28 (5): 1050-62.
512 513 514	34.	Smith M, Abdesselem HB, Mullins M, et al. Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort. <i>Viruses</i> 2021; 13 (5).
515 516 517 518	35.	Martin CA, Nazareth J, Jarkhi A, et al. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis. <i>EClinicalMedicine</i> 2023; 58 : 101926.









Figure 3

Figure 4

